131 related articles for article (PubMed ID: 14682132)
1. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
Ivanov SD; Iamshanov VA; Korytova LI; Khazova TV; Arzumanov AS
Vopr Onkol; 2003; 49(5):601-7. PubMed ID: 14682132
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
3. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
4. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
5. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
6. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
7. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
Livi L; Saieva C; Borghesi S; Paoletti L; Meattini I; Rampini A; Petrucci A; Scoccianti S; Paiar F; Cataliotti L; Leonulli BG; Bianchi S; Biti GP
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):705-9. PubMed ID: 18191333
[TBL] [Abstract][Full Text] [Related]
8. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer.
Arcangeli G; Pinnarò P; Rambone R; Giannarelli D; Benassi M
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):161-7. PubMed ID: 16226397
[TBL] [Abstract][Full Text] [Related]
9. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
10. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
[TBL] [Abstract][Full Text] [Related]
11. [Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
Hofmann M; Mahlke M; Casper F; Brockerhoff P
Zentralbl Gynakol; 1995; 117(6):314-6. PubMed ID: 7544054
[TBL] [Abstract][Full Text] [Related]
12. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842
[TBL] [Abstract][Full Text] [Related]
13. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
[TBL] [Abstract][Full Text] [Related]
14. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
15. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
[TBL] [Abstract][Full Text] [Related]
16. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; van Dam FS
Breast Cancer Res Treat; 2005 Nov; 94(1):53-61. PubMed ID: 16175317
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
Rouëssé J; de la Lande B; Bertheault-Cvitkovic F; Serin D; Graïc Y; Combe M; Leduc B; Lucas V; Demange L; Nguyen TD; Castèra D; Krzisch C; Villet R; Mouret-Fourme E; Garbay JR; Noguès C;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1072-80. PubMed ID: 16504757
[TBL] [Abstract][Full Text] [Related]
20. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
De Maio E; Gravina A; Pacilio C; Amabile G; Labonia V; Landi G; Nuzzo F; Rossi E; D'Aiuto G; Capasso I; Rinaldo M; Morrica B; Elmo M; Di Maio M; Perrone F; de Matteis A
BMC Cancer; 2005 Mar; 5():30. PubMed ID: 15790416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
